- Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China;
Yang Liu,
Email: liu_yang@bjmu.edu.cn
Pediatric uveitis is an inflammatory disease involving iris, ciliary body and choroid. Compared with adult uveitis, pediatric uveitis has insidious onset and is easy to delay treatment. In recent years, biological agents have made remarkable progress in the treatment of non-infectious uveitis (NIU) in children. Anti-tumor necrosis factor-alpha drugs represented by Adalimumab have shown good effects in the control of inflammation, the saving of glucocorticoids, the frequency of uveitis attacks and the improvement of visual prognosis. At the same time, other biologics such as B cell antagonists, T cell antagonists, interleukin-6 antagonists and Janus kinase inhibitors were also gradually tested in children with NIU, bringing good news to children who failed to respond to anti-tumor necrosis factor-alpha drugs. With the in-depth understanding of the diagnosis and treatment of NIU children by clinicians, as well as the characteristics and therapeutic application of various biological agents, it is helpful to develop a more diversified and individualized treatment plan for children, so as to save the vision of children and children's families.
Citation： Zhang Zhiyue, Yang Liu. Research progress in clinical application of biologic agents for use in treatment of pediatric non-infectious uveitis. Chinese Journal of Ocular Fundus Diseases, 2025, 41(7): 555-560. doi: 10.3760/cma.j.cn511434-20241121-00440 Copy
Copyright © the editorial department of Chinese Journal of Ocular Fundus Diseases of West China Medical Publisher. All rights reserved
| 1. | Edelsten C, Reddy MA, Stanford MR, et al. Visual loss associated with pediatric uveitis in English primary and referral centers[J]. Am J Ophthalmol, 2003, 135(5): 676-680. DOI: 10.1016/s0002-9394(02)02148-7. |
| 2. | Modrzejewska M, Zdanowska O. Diagnosis and treatment of uveitis in children: a summary of the latest data from a 5-year literature review (2018-2023)[J/OL]. J Clin Med, 2024, 13(11): 3097[2024-05-25]. https://pubmed.ncbi.nlm.nih.gov/38892808/. DOI: 10.3390/jcm13113097. |
| 3. | Maleki A, Anesi SD, Look-Why S, et al. Pediatric uveitis: a comprehensive review[J]. Surv Ophthalmol, 2022, 67(2): 510-529. DOI: 10.1016/j.survophthal.2021.06.006. |
| 4. | Abdwani R. Challenges of childhood uveitis[J]. Sultan Qaboos Univ Med J, 2009, 9(3): 247-256. |
| 5. | Cann M, Ramanan AV, Crawford A, et al. Outcomes of non-infectious paediatric uveitis in the era of biologic therapy[J]. Pediatr Rheumatol, 2018, 16(1): 51. DOI: 10.1186/s12969-018-0266-5. |
| 6. | Maleki A, Patel PD, Foster CS. Juvenile idiopathic arthritis and its associated uveitis[J]. Expert Rev Clin Immunol, 2023, 19(9): 1157-1169. DOI: 10.1080/1744666X.2023.2231154. |
| 7. | Leal I, Steeples LR, Wong SW, et al. Update on the systemic management of noninfectious uveitis in children and adolescents[J]. Surv Ophthalmol, 2024, 69(1): 103-121. DOI: 10.1016/j.survophthal.2023.01.002. |
| 8. | Rosenbaum J, Pasadhika S. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis[J]. Biol Targets Ther, 2014, 8: 67-81. DOI: 10.2147/BTT.S41477. |
| 9. | Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India[J]. Indian J Ophthalmol, 2020, 68(9): 1929-1933. DOI: 10.4103/ijo.IJO_966_20. |
| 10. | Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors[J]. J Rheumatol, 2013, 40(8): 1394-1403. DOI: 10.3899/jrheum.121180. |
| 11. | Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis[J]. Surv Ophthalmol, 2015, 60(6): 575-589. DOI: 10.1016/j.survophthal.2015.06.004. |
| 12. | Sood AB, Angeles-Han ST. An update on treatment of pediatric chronic non-infectious uveitis[J]. Curr Treat Options Rheumatol, 2017, 3(1): 1-16. DOI: 10.1007/s40674-017-0057-z. |
| 13. | Vassalli P. The pathophysiology of tumor necrosis factors[J]. Annu Rev Immunol, 1992, 10(1): 411-452. DOI: 10.1146/annurev.iy.10.040192.002211. |
| 14. | 程卫东, 张美芬. 儿童非感染性葡萄膜炎药物治疗研究进展[J]. 中华眼科杂志, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.Chen WD, Zhang MF. Research progress of medication treatment of pediatric noninfectious uveitis[J]. Chin J Ophthalmol, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324. |
| 15. | Giani T, Luppino AF, Ferrara G. Treatment options in pediatric Behçet’s disease[J]. Pediatr Drugs, 2023, 25(2): 165-191. DOI: 10.1007/s40272-022-00548-5. |
| 16. | 池滢, 杨柳. 关注TNF-α抑制剂在葡萄膜炎治疗中存在的感染和肿瘤发生及进展风险[J]. 中华实验眼科杂志, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.Chi Y, Yang L. Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis[J]. Chin J Exp Ophthalmol, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571. |
| 17. | 海峡两岸医药卫生交流协会风湿免疫分会眼免疫学组. 抗肿瘤坏死因子-α单克隆抗体治疗非感染性葡萄膜炎中国专家共识[J]. 中华眼底病杂志, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-004735.Ophthalmoimmunology Group, Rheumatism Immunology Branch, Cross-Straits Medical and Health Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-004735. |
| 18. | Çakar Özdal P. Behçet’s uveitis: current diagnostic and therapeutic approach[J]. Turk J Ophthalmol, 2020, 50(3): 169-182. DOI: 10.4274/tjo.galenos.2019.60308. |
| 19. | Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis[J]. Drug Des Devel Ther, 2016, 10: 2997-3003. DOI: 10.2147/DDDT.S94188. |
| 20. | Quartier P, Baptiste A, Despert V, et al. A double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003-1011. DOI: 10.1136/annrheumdis-2017-212089. |
| 21. | Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis[J]. N Engl J Med, 2017, 376(17): 1637-1646. DOI: 10.1056/NEJMoa1614160. |
| 22. | Kouwenberg CV, Koopman-Kalinina Ayuso V, De Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012. |
| 23. | Tirelli F, Shafer BM, Davidson SL, et al. Immunomodulation and TNF-α inhibition for tubulointerstitial nephritis and uveitis syndrome: a case series[J]. J AAPOS, 2021, 25(5): 267. DOI: 10.1016/j.jaapos.2021.03.017. |
| 24. | Matsuo T, Yashiro M. Long-term control of macular edema with adalimumab after cataract surgery in a japanese child with juvenile idiopathic arthritis: case report and review of 26 Japanese patients[J/OL]. J Investig Med High Impact Case Rep, 2020, 8: 2324709620953283[2020-08-29]. https://pubmed.ncbi.nlm.nih.gov/32862718/. DOI: 10.1177/2324709620953283. |
| 25. | Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study[J]. Ocul Immunol Inflamm, 2016, 24(3): 319-326. DOI: 10.3109/09273948.2014.990041. |
| 26. | Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(4): 482-491. DOI: 10.1002/acr.23610. |
| 27. | Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis[J]. Semin Arthritis Rheum, 2019, 49(1): 43-55. DOI: 10.1016/j.semarthrit.2018.11.004. |
| 28. | Horton S, Jones AP, Guly CM, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial[J]. Am J Ophthalmol, 2019, 207: 170-174. DOI: 10.1016/j.ajo.2019.06.007. |
| 29. | Holroyd CR, Seth R, Bukhari M, et al. The british society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis-executive summary[J]. Rheumatology, 2019, 58(2): 220-226. DOI: 10.1093/rheumatology/key207. |
| 30. | Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060. |
| 31. | Bitoun S, Hässler S, Ternant D, et al. Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies[J/OL]. JAMA Netw Open, 2023, 6(7): e2323098[2023-07-03]. https://pubmed.ncbi.nlm.nih.gov/37436748/. DOI: 10.1001/jamanetworkopen.2023.23098. |
| 32. | Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584. |
| 33. | Dehoorne JL, Groth H, Carlé E, et al. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment[J]. Pediatr Rheumatol, 2023, 21(1): 148. DOI: 10.1186/s12969-023-00928-932. |
| 34. | Roberts JE, Nigrovic PA, Lo MS, et al. Weekly adalimumab, an effective alternative for refractory uveitis in children[J/OL]. J Clin Rheumatol, 2022, 28(1): e301-e304[2022-01-01]. https://pubmed.ncbi.nlm.nih.gov/33790207/. DOI: 10.1097/RHU.0000000000001707. |
| 35. | Huard J, Mihailescu SD, Muraine M, et al. Effectiveness and safety of weekly adalimumab for non-infectious chronic anterior uveitis in children[J]. Ocul Immunol Inflamm, 2023, 31(10): 2039-2049. DOI: 10.1080/09273948.2023.2279682. |
| 36. | Foeldvari I, Petrushkin H. How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?[J]. Expert Rev Clin Immunol, 2024, 20(3): 267-276. DOI: 10.1080/1744666X.2023.2284845. |
| 37. | Maccora I, Soldovieri S, Oliverio T, et al. To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the Ⅰ anti-TNF[J/OL]. J Transl Autoimmun, 2024, 9: 100247[2024-06-22]. https://pubmed.ncbi.nlm.nih.gov/39027719/. DOI: 10.1016/j.jtauto.2024.100247. |
| 38. | Ashkenazy N, Saboo US, Abraham A, et al. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis[J]. J AAPOS, 2019, 23(3): 151. DOI: 10.1016/j.jaapos.2019.02.006. |
| 39. | Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis[J]. Pediatr Rheumatol, 2019, 17(1): 79. DOI: 10.1186/s12969-019-0383-9. |
| 40. | Kreps EO, Epps SJ, Consejo A, et al. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy[J]. Eye, 2024, 38(5): 871-876. DOI: 10.1038/s41433-023-02795-3. |
| 41. | Norcia LF, Kiappe OP, Jorge EC. Biological therapy in noninfectious pediatric uveitis: a systematic review[J]. Clin Ophthalmol, 2021, 15: 3765-3776. DOI: 10.2147/OPTH.S322445. |
| 42. | Maalouf G, Andrillon A, Leclercq M, et al. Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: a multicenter study of 330 patients[J]. Am J Ophthalmol, 2022, 238: 173-180. DOI: 10.1016/j.ajo.2022.02.002. |
| 43. | Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases[J]. Arthritis Rheumatol, 2019, 71(12): 2081-2089. DOI: 10.1002/art.41026. |
| 44. | Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2018, 45(8): 1167-1172. DOI: 10.3899/jrheum.171006. |
| 45. | Tai F, Mehraban Far P, Pechlivanoglou P, et al. Efficacy and safety of adalimumab and infliximab for noninfectious uveitis[J]. Ophthalmology, 2022, 129(3): 357-359. DOI: 10.1016/j.ophtha.2021.09.025. |
| 46. | Cordero-Coma M, Salom D, Díaz-Llopis M, et al. Golimumab for uveitis[J]. Ophthalmology, 2011, 118(9): 1892-1894. DOI: 10.1016/j.ophtha.2011.05.019. |
| 47. | Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to adalimumab[J]. Pediatr Rheumatol, 2021, 19(1): 132. DOI: 10.1186/s12969-021-00630-1. |
| 48. | Armaroli G, Klein A, Ganser G, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry[J]. Arthritis Res Ther, 2020, 22(1): 258. DOI: 10.1186/s13075-020-02326-5. |
| 49. | Semeraro F, Arcidiacono B, Nascimbeni G, et al. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis[J]. Drug Des Devel Ther, 2014, 8: 341-348. DOI: 10.2147/DDDT.S54207. |
| 50. | Li Y, Mao X, Tang X, et al. Efficacy and safety of anti-TNFα therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis[J]. Rheumatol Ther, 2021, 8(2): 711-727. DOI: 10.1007/s40744-021-00296-x. |
| 51. | Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716. DOI: 10.1002/acr.23871. |
| 52. | Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis[J]. Pediatr Rheumatol Online J, 2016, 14(1): 27. DOI: 10.1186/s12969-016-0088-2. |
| 53. | Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases[J]. Autoimmun Rev, 2011, 11(1): 35-39. DOI: 10.1016/j.autrev.2011.07.001. |
| 54. | Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis[J]. Br J Ophthalmol, 2016, 100(6): 782-786. DOI: 10.1136/bjophthalmol-2015-306790. |
| 55. | Bitossi A, Mattioli I, Bettiol A, et al. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review[J]. Expert Rev Clin Immunol, 2023, 19(5): 549-560. DOI: 10.1080/1744666X.2023.2193687. |
| 56. | Gaffney KJ, Dahl EM, Stanton MP, et al. Rapid-infusion rituximab in a pediatric population[J]. J Pediatr Pharmacol Ther, 2020, 25(3): 215-219. DOI: 10.5863/1551-6776-25.3.215. |
| 57. | Miserocchi E, Modorati G. Rituximab for noninfectious uveitis[J]. Dev Ophthalmol, 2012, 51: 98-109. DOI: 10.1159/000336188. |
| 58. | Kim L, Li A, Angeles-Han S, et al. Update on the management of uveitis in children: an overview for the clinician[J]. Expert Rev Ophthalmol, 2019, 14(4-5): 211-218. DOI: 10.1080/17469899.2019.1663731. |
| 59. | Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation[J]. J Am Soc Nephrol, 2002, 13(2): 559-575. DOI: 10.1681/ASN.V132559. |
| 60. | Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2015, 42(4): 706-711. DOI: 10.3899/jrheum.140410. |
| 61. | Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis[J]. J Rheumatol, 2016, 43(11): 2068-2073. DOI: 10.3899/jrheum.151389. |
| 62. | Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al. Biological and therapeutic role of interleukin-6 in non-infectious uveitis: a narrative review[J]. Ocul Immunol Inflamm, 2024, 15: 1-15. DOI: 10.1080/09273948.2024.2408401. |
| 63. | Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-interleukin‐6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients[J]. Arthritis Rheumatol, 2017, 69(3): 668-675. DOI: 10.1002/art.39940. |
| 64. | Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis[J]. Ocul Immunol Inflamm, 2021, 29(1): 14-20. DOI: 10.1080/09273948.2020.1817501. |
| 65. | Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience[J/OL]. Front Pediatr, 2022, 10: 851453[2022-04-12]. https://pubmed.ncbi.nlm.nih.gov/35498797/. DOI: 10.3389/fped.2022.851453. |
| 66. | Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family[J]. Int Immunopharmacol, 2005, 5(12): 1731-1740. DOI: 10.1016/j.intimp.2005.05.010. |
| 67. | Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050[J]. J Immunol, 2010, 184(9): 5298-5307. DOI: 10.4049/jimmunol.0902819. |
| 68. | Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis[J]. Clin Rheumatol, 2020, 39(3): 847-851. DOI: 10.1007/s10067-019-04875-w. |
| 69. | Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)[J]. Trials, 2021, 22(1): 689. DOI: 10.1186/s13063-021-05651-5. |
| 70. | Dutta Majumder P, Abraham S, Sudharshan S, et al. Tofacitinib for refractory uveitis and scleritis in children: a case series[J]. Ocul Immunol Inflamm, 2024, 32(9): 2092-2095. DOI: 10.1080/09273948.2024.2323671. |
| 71. | Leclercq M, Desbois AC, Domont F, et al. Biotherapies in uveitis[J/OL]. J Clin Med, 2020, 9(11): 3599[2020-11-08]. https://pubmed.ncbi.nlm.nih.gov/33171664/. DOI: 10.3390/jcm9113599. |
| 72. | Miserocchi E, Giuffre C, Caporali R, et al. Secukinumab in HLA-B27 associated uveitis[J]. Clin Experiment Ophthalmol, 2021, 49(4): 388-389. DOI: 10.1111/ceo.13922. |
| 73. | Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials[J]. Ophthalmology, 2013, 120(4): 777-787. DOI: 10.1016/j.ophtha.2012.09.040. |
| 74. | Heissigerová J, Callanan D, De Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study[J]. Ophthalmology, 2019, 126(3): 428-437. DOI: 10.1016/j.ophtha.2018.09.044. |
| 75. | Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in behçet’s disease-related uveitis: a multicenter retrospective observational study[J]. Clin Rheumatol, 2017, 36(1): 191-197. DOI: 10.1007/s10067-016-3506-4. |
| 76. | Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131. |
| 77. | Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis[J]. Arthritis Care Res, 2023, 75(5): 975-982. DOI: 10.1002/acr.24963. |
- 1. Edelsten C, Reddy MA, Stanford MR, et al. Visual loss associated with pediatric uveitis in English primary and referral centers[J]. Am J Ophthalmol, 2003, 135(5): 676-680. DOI: 10.1016/s0002-9394(02)02148-7.
- 2. Modrzejewska M, Zdanowska O. Diagnosis and treatment of uveitis in children: a summary of the latest data from a 5-year literature review (2018-2023)[J/OL]. J Clin Med, 2024, 13(11): 3097[2024-05-25]. https://pubmed.ncbi.nlm.nih.gov/38892808/. DOI: 10.3390/jcm13113097.
- 3. Maleki A, Anesi SD, Look-Why S, et al. Pediatric uveitis: a comprehensive review[J]. Surv Ophthalmol, 2022, 67(2): 510-529. DOI: 10.1016/j.survophthal.2021.06.006.
- 4. Abdwani R. Challenges of childhood uveitis[J]. Sultan Qaboos Univ Med J, 2009, 9(3): 247-256.
- 5. Cann M, Ramanan AV, Crawford A, et al. Outcomes of non-infectious paediatric uveitis in the era of biologic therapy[J]. Pediatr Rheumatol, 2018, 16(1): 51. DOI: 10.1186/s12969-018-0266-5.
- 6. Maleki A, Patel PD, Foster CS. Juvenile idiopathic arthritis and its associated uveitis[J]. Expert Rev Clin Immunol, 2023, 19(9): 1157-1169. DOI: 10.1080/1744666X.2023.2231154.
- 7. Leal I, Steeples LR, Wong SW, et al. Update on the systemic management of noninfectious uveitis in children and adolescents[J]. Surv Ophthalmol, 2024, 69(1): 103-121. DOI: 10.1016/j.survophthal.2023.01.002.
- 8. Rosenbaum J, Pasadhika S. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis[J]. Biol Targets Ther, 2014, 8: 67-81. DOI: 10.2147/BTT.S41477.
- 9. Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India[J]. Indian J Ophthalmol, 2020, 68(9): 1929-1933. DOI: 10.4103/ijo.IJO_966_20.
- 10. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors[J]. J Rheumatol, 2013, 40(8): 1394-1403. DOI: 10.3899/jrheum.121180.
- 11. Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis[J]. Surv Ophthalmol, 2015, 60(6): 575-589. DOI: 10.1016/j.survophthal.2015.06.004.
- 12. Sood AB, Angeles-Han ST. An update on treatment of pediatric chronic non-infectious uveitis[J]. Curr Treat Options Rheumatol, 2017, 3(1): 1-16. DOI: 10.1007/s40674-017-0057-z.
- 13. Vassalli P. The pathophysiology of tumor necrosis factors[J]. Annu Rev Immunol, 1992, 10(1): 411-452. DOI: 10.1146/annurev.iy.10.040192.002211.
- 14. 程卫东, 张美芬. 儿童非感染性葡萄膜炎药物治疗研究进展[J]. 中华眼科杂志, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.Chen WD, Zhang MF. Research progress of medication treatment of pediatric noninfectious uveitis[J]. Chin J Ophthalmol, 2023, 59(3): 231-236. DOI: 10.3760/cma.j.cn112142-20220703-00324.
- 15. Giani T, Luppino AF, Ferrara G. Treatment options in pediatric Behçet’s disease[J]. Pediatr Drugs, 2023, 25(2): 165-191. DOI: 10.1007/s40272-022-00548-5.
- 16. 池滢, 杨柳. 关注TNF-α抑制剂在葡萄膜炎治疗中存在的感染和肿瘤发生及进展风险[J]. 中华实验眼科杂志, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.Chi Y, Yang L. Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis[J]. Chin J Exp Ophthalmol, 2021, 39(11): 929-932. DOI: 10.3760/cma.j.cn115989-20211020-00571.
- 17. 海峡两岸医药卫生交流协会风湿免疫分会眼免疫学组. 抗肿瘤坏死因子-α单克隆抗体治疗非感染性葡萄膜炎中国专家共识[J]. 中华眼底病杂志, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-004735.Ophthalmoimmunology Group, Rheumatism Immunology Branch, Cross-Straits Medical and Health Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody[J]. Chin J Ocul Fundus Dis, 2024, 40(1): 8-19. DOI: 10.3760/cma.j.cn511434-20231201-004735.
- 18. Çakar Özdal P. Behçet’s uveitis: current diagnostic and therapeutic approach[J]. Turk J Ophthalmol, 2020, 50(3): 169-182. DOI: 10.4274/tjo.galenos.2019.60308.
- 19. Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis[J]. Drug Des Devel Ther, 2016, 10: 2997-3003. DOI: 10.2147/DDDT.S94188.
- 20. Quartier P, Baptiste A, Despert V, et al. A double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003-1011. DOI: 10.1136/annrheumdis-2017-212089.
- 21. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis[J]. N Engl J Med, 2017, 376(17): 1637-1646. DOI: 10.1056/NEJMoa1614160.
- 22. Kouwenberg CV, Koopman-Kalinina Ayuso V, De Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
- 23. Tirelli F, Shafer BM, Davidson SL, et al. Immunomodulation and TNF-α inhibition for tubulointerstitial nephritis and uveitis syndrome: a case series[J]. J AAPOS, 2021, 25(5): 267. DOI: 10.1016/j.jaapos.2021.03.017.
- 24. Matsuo T, Yashiro M. Long-term control of macular edema with adalimumab after cataract surgery in a japanese child with juvenile idiopathic arthritis: case report and review of 26 Japanese patients[J/OL]. J Investig Med High Impact Case Rep, 2020, 8: 2324709620953283[2020-08-29]. https://pubmed.ncbi.nlm.nih.gov/32862718/. DOI: 10.1177/2324709620953283.
- 25. Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study[J]. Ocul Immunol Inflamm, 2016, 24(3): 319-326. DOI: 10.3109/09273948.2014.990041.
- 26. Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
- 27. Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis[J]. Semin Arthritis Rheum, 2019, 49(1): 43-55. DOI: 10.1016/j.semarthrit.2018.11.004.
- 28. Horton S, Jones AP, Guly CM, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial[J]. Am J Ophthalmol, 2019, 207: 170-174. DOI: 10.1016/j.ajo.2019.06.007.
- 29. Holroyd CR, Seth R, Bukhari M, et al. The british society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis-executive summary[J]. Rheumatology, 2019, 58(2): 220-226. DOI: 10.1093/rheumatology/key207.
- 30. Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
- 31. Bitoun S, Hässler S, Ternant D, et al. Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies[J/OL]. JAMA Netw Open, 2023, 6(7): e2323098[2023-07-03]. https://pubmed.ncbi.nlm.nih.gov/37436748/. DOI: 10.1001/jamanetworkopen.2023.23098.
- 32. Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
- 33. Dehoorne JL, Groth H, Carlé E, et al. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment[J]. Pediatr Rheumatol, 2023, 21(1): 148. DOI: 10.1186/s12969-023-00928-932.
- 34. Roberts JE, Nigrovic PA, Lo MS, et al. Weekly adalimumab, an effective alternative for refractory uveitis in children[J/OL]. J Clin Rheumatol, 2022, 28(1): e301-e304[2022-01-01]. https://pubmed.ncbi.nlm.nih.gov/33790207/. DOI: 10.1097/RHU.0000000000001707.
- 35. Huard J, Mihailescu SD, Muraine M, et al. Effectiveness and safety of weekly adalimumab for non-infectious chronic anterior uveitis in children[J]. Ocul Immunol Inflamm, 2023, 31(10): 2039-2049. DOI: 10.1080/09273948.2023.2279682.
- 36. Foeldvari I, Petrushkin H. How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?[J]. Expert Rev Clin Immunol, 2024, 20(3): 267-276. DOI: 10.1080/1744666X.2023.2284845.
- 37. Maccora I, Soldovieri S, Oliverio T, et al. To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the Ⅰ anti-TNF[J/OL]. J Transl Autoimmun, 2024, 9: 100247[2024-06-22]. https://pubmed.ncbi.nlm.nih.gov/39027719/. DOI: 10.1016/j.jtauto.2024.100247.
- 38. Ashkenazy N, Saboo US, Abraham A, et al. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis[J]. J AAPOS, 2019, 23(3): 151. DOI: 10.1016/j.jaapos.2019.02.006.
- 39. Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis[J]. Pediatr Rheumatol, 2019, 17(1): 79. DOI: 10.1186/s12969-019-0383-9.
- 40. Kreps EO, Epps SJ, Consejo A, et al. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy[J]. Eye, 2024, 38(5): 871-876. DOI: 10.1038/s41433-023-02795-3.
- 41. Norcia LF, Kiappe OP, Jorge EC. Biological therapy in noninfectious pediatric uveitis: a systematic review[J]. Clin Ophthalmol, 2021, 15: 3765-3776. DOI: 10.2147/OPTH.S322445.
- 42. Maalouf G, Andrillon A, Leclercq M, et al. Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: a multicenter study of 330 patients[J]. Am J Ophthalmol, 2022, 238: 173-180. DOI: 10.1016/j.ajo.2022.02.002.
- 43. Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases[J]. Arthritis Rheumatol, 2019, 71(12): 2081-2089. DOI: 10.1002/art.41026.
- 44. Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2018, 45(8): 1167-1172. DOI: 10.3899/jrheum.171006.
- 45. Tai F, Mehraban Far P, Pechlivanoglou P, et al. Efficacy and safety of adalimumab and infliximab for noninfectious uveitis[J]. Ophthalmology, 2022, 129(3): 357-359. DOI: 10.1016/j.ophtha.2021.09.025.
- 46. Cordero-Coma M, Salom D, Díaz-Llopis M, et al. Golimumab for uveitis[J]. Ophthalmology, 2011, 118(9): 1892-1894. DOI: 10.1016/j.ophtha.2011.05.019.
- 47. Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to adalimumab[J]. Pediatr Rheumatol, 2021, 19(1): 132. DOI: 10.1186/s12969-021-00630-1.
- 48. Armaroli G, Klein A, Ganser G, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry[J]. Arthritis Res Ther, 2020, 22(1): 258. DOI: 10.1186/s13075-020-02326-5.
- 49. Semeraro F, Arcidiacono B, Nascimbeni G, et al. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis[J]. Drug Des Devel Ther, 2014, 8: 341-348. DOI: 10.2147/DDDT.S54207.
- 50. Li Y, Mao X, Tang X, et al. Efficacy and safety of anti-TNFα therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis[J]. Rheumatol Ther, 2021, 8(2): 711-727. DOI: 10.1007/s40744-021-00296-x.
- 51. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716. DOI: 10.1002/acr.23871.
- 52. Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis[J]. Pediatr Rheumatol Online J, 2016, 14(1): 27. DOI: 10.1186/s12969-016-0088-2.
- 53. Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases[J]. Autoimmun Rev, 2011, 11(1): 35-39. DOI: 10.1016/j.autrev.2011.07.001.
- 54. Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis[J]. Br J Ophthalmol, 2016, 100(6): 782-786. DOI: 10.1136/bjophthalmol-2015-306790.
- 55. Bitossi A, Mattioli I, Bettiol A, et al. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review[J]. Expert Rev Clin Immunol, 2023, 19(5): 549-560. DOI: 10.1080/1744666X.2023.2193687.
- 56. Gaffney KJ, Dahl EM, Stanton MP, et al. Rapid-infusion rituximab in a pediatric population[J]. J Pediatr Pharmacol Ther, 2020, 25(3): 215-219. DOI: 10.5863/1551-6776-25.3.215.
- 57. Miserocchi E, Modorati G. Rituximab for noninfectious uveitis[J]. Dev Ophthalmol, 2012, 51: 98-109. DOI: 10.1159/000336188.
- 58. Kim L, Li A, Angeles-Han S, et al. Update on the management of uveitis in children: an overview for the clinician[J]. Expert Rev Ophthalmol, 2019, 14(4-5): 211-218. DOI: 10.1080/17469899.2019.1663731.
- 59. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation[J]. J Am Soc Nephrol, 2002, 13(2): 559-575. DOI: 10.1681/ASN.V132559.
- 60. Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2015, 42(4): 706-711. DOI: 10.3899/jrheum.140410.
- 61. Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis[J]. J Rheumatol, 2016, 43(11): 2068-2073. DOI: 10.3899/jrheum.151389.
- 62. Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al. Biological and therapeutic role of interleukin-6 in non-infectious uveitis: a narrative review[J]. Ocul Immunol Inflamm, 2024, 15: 1-15. DOI: 10.1080/09273948.2024.2408401.
- 63. Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-interleukin‐6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients[J]. Arthritis Rheumatol, 2017, 69(3): 668-675. DOI: 10.1002/art.39940.
- 64. Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis[J]. Ocul Immunol Inflamm, 2021, 29(1): 14-20. DOI: 10.1080/09273948.2020.1817501.
- 65. Maccora I, Abu Rumeileh S, Curci F, et al. Tocilizumab and abatacept for the treatment of childhood chronic uveitis: a monocentric comparison experience[J/OL]. Front Pediatr, 2022, 10: 851453[2022-04-12]. https://pubmed.ncbi.nlm.nih.gov/35498797/. DOI: 10.3389/fped.2022.851453.
- 66. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family[J]. Int Immunopharmacol, 2005, 5(12): 1731-1740. DOI: 10.1016/j.intimp.2005.05.010.
- 67. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050[J]. J Immunol, 2010, 184(9): 5298-5307. DOI: 10.4049/jimmunol.0902819.
- 68. Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis[J]. Clin Rheumatol, 2020, 39(3): 847-851. DOI: 10.1007/s10067-019-04875-w.
- 69. Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)[J]. Trials, 2021, 22(1): 689. DOI: 10.1186/s13063-021-05651-5.
- 70. Dutta Majumder P, Abraham S, Sudharshan S, et al. Tofacitinib for refractory uveitis and scleritis in children: a case series[J]. Ocul Immunol Inflamm, 2024, 32(9): 2092-2095. DOI: 10.1080/09273948.2024.2323671.
- 71. Leclercq M, Desbois AC, Domont F, et al. Biotherapies in uveitis[J/OL]. J Clin Med, 2020, 9(11): 3599[2020-11-08]. https://pubmed.ncbi.nlm.nih.gov/33171664/. DOI: 10.3390/jcm9113599.
- 72. Miserocchi E, Giuffre C, Caporali R, et al. Secukinumab in HLA-B27 associated uveitis[J]. Clin Experiment Ophthalmol, 2021, 49(4): 388-389. DOI: 10.1111/ceo.13922.
- 73. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials[J]. Ophthalmology, 2013, 120(4): 777-787. DOI: 10.1016/j.ophtha.2012.09.040.
- 74. Heissigerová J, Callanan D, De Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study[J]. Ophthalmology, 2019, 126(3): 428-437. DOI: 10.1016/j.ophtha.2018.09.044.
- 75. Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in behçet’s disease-related uveitis: a multicenter retrospective observational study[J]. Clin Rheumatol, 2017, 36(1): 191-197. DOI: 10.1007/s10067-016-3506-4.
- 76. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131.
- 77. Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis[J]. Arthritis Care Res, 2023, 75(5): 975-982. DOI: 10.1002/acr.24963.